SEBI has granted in-principle approval to 1 Finance to set up India's first MF Lite asset management company, targeting a Q4 FY27 launch. MF Lite is a lighter regulatory framework introduced by SEBI for passively managed mutual funds, with lower net-worth requirements and simplified compliance compared to full-service AMCs. This marks the first time any entity has received approval under the MF Lite framework since SEBI introduced the concept.

MF Lite is a regulatory framework SEBI introduced to expand mutual fund penetration by lowering barriers to entry for new asset management companies — specifically those offering only passive funds such as index funds and exchange-traded funds (ETFs). Unlike conventional AMCs that can launch actively managed schemes, MF Lite AMCs are restricted to passive products, which carry lower fund-management risk and need less intensive regulatory oversight.

The key differentiators of MF Lite from full-service AMC regulations include reduced minimum net-worth requirements and a simplified compliance structure. SEBI's rationale is that passive funds carry lower manager risk since they track an index mechanically, so lighter oversight is proportionate. The move is designed to attract new, smaller players into a market dominated by large established fund houses.

'In-principle approval' is an important procedural distinction: it signals SEBI's intent to grant the final licence but requires the applicant to fulfil certain conditions — infrastructure, key personnel appointments, and systems — before a final Certificate of Registration is issued. The approval does not permit the entity to begin operations immediately.

For SEBI Grade A aspirants, this event connects directly to testable static knowledge: the definition and scope of MF Lite, the categories of schemes permissible under it, and the registration process for AMCs under SEBI (Mutual Funds) Regulations, 1996. The examiner can also test the distinction between active and passive funds, and the regulatory rationale for differential treatment.